PLCG2 as a Radioligand Therapy Target
PLCG2, phospholipase C gamma 2, is a cell-surface protein. In Human Protein Atlas immunohistochemistry, PLCG2 staining is highest in lymphoma (100% of samples positive), head and neck cancer (100% of samples positive) and thyroid cancer (100% of samples positive). Clinical status: Discovery-stage (no clinical drug program).
Is PLCG2 a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in lymphoma, 100% of samples positive.
- ❔ Internalization: Not yet assessed.
- ⚠️ Clinical precedent: Discovery-stage (no clinical drug program)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
PLCG2 expression in cancer
Protein expression of PLCG2 across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Lymphoma | 0.97 | High | 100% |
| Head and Neck Cancer | 0.67 | High | 100% |
| Thyroid Cancer | 0.58 | High | 100% |
| Ovarian Cancer | 0.47 | Medium | 100% |
| Pancreatic Cancer | 0.47 | Medium | 100% |
| Liver Cancer | 0.47 | Medium | 100% |
| Cervical Cancer | 0.44 | Medium | 100% |
| Melanoma | 0.42 | Medium | 100% |
| Neuroendocrine Tumors | 0.42 | Medium | 100% |
| Breast Cancer | 0.39 | Medium | 91% |
| Bladder Cancer | 0.39 | Medium | 100% |
| Testicular Cancer | 0.39 | Medium | 100% |
| Gastric Cancer | 0.39 | Medium | 83% |
| Colorectal Cancer | 0.36 | Medium | 100% |
| Skin Cancer | 0.33 | Medium | 100% |
| Prostate Cancer | 0.33 | Medium | 100% |
| Endometrial Cancer | 0.33 | Medium | 91% |
| Lung Cancer | 0.30 | Medium | 91% |
| Kidney Cancer | 0.28 | Medium | 83% |
Not detected by IHC in: glioma.
Is PLCG2 internalized?
Nuclens has not yet extracted internalization evidence for PLCG2. Internalization matters for radioligands because an internalizing receptor traps the radionuclide inside the tumor cell. Run a full analysis to pull the latest literature.
PLCG2 clinical trials
Discovery-stage (no clinical drug program). Nuclens hasn't indexed trials for PLCG2 yet. Search ClinicalTrials.gov for PLCG2 trials.
PLCG2 normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See PLCG2 in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
PLCG2 gene essentiality (DepMap)
CRISPR knockout effect across 1257 cancer cell lines: 0.11 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related lymphoma radioligand targets
c-MET (MET) · CD20 (MS4A1) · HER3 (ERBB3) · CD45 (PTPRC) · CD19 · SSTR2 · STEAP2 · CD22
See all radioligand therapy targets in lymphoma.
See how PLCG2 ranks against 15,000 targets for your indication.
Run a free analysisData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.